| Date Filed | Type | Description |
| 02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 05/17/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 04/12/2021 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 04/08/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/06/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/06/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/01/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/01/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/01/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 04/01/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 04/01/2021 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
| 04/01/2021 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 04/01/2021 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 04/01/2021 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 03/31/2021 |
10-K/A
| Annual Report for the period ended December 31, 2020 [amend] |
| 03/22/2021 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 03/22/2021 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 03/12/2021 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/12/2021 |
10-K
| Annual Report for the period ended December 31, 2020 |
| 03/04/2021 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 03/04/2021 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 03/04/2021 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 03/04/2021 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 02/26/2021 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 02/25/2021 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 02/25/2021 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 02/25/2021 |
8-K
| Quarterly results |
| 02/16/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/16/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/12/2021 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/04/2021 |
8-K
| Quarterly results |
| 12/03/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Pandion Therapeutics Appoints Katina Dorton to its Board of Directors WATERTOWN, Mass. - December 3, 2020 - Pandion Therapeutics, Inc. , a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the appointment of Katina Dorton, J.D., M.B.A., to Pandion's board of directors and as chair of the audit committee. Ms. Dorton assumes the position of chair of the audit committee from Christopher Fuglesang, Ph.D., J.D., who will continue to serve as a member of the board and audit committee. Mitchell Mutz, Ph.D., resigned from the Company's board on December 2, 2020. “Ms. Dorton brings to Pandion over two decades of financial expertise, leading a multitude of financial transactions for comp..." |
|
| 11/16/2020 |
10-Q
| Quarterly Report for the period ended September 30, 2020 |
|